Application
A. Western blot analysis on Hela cell lysate using anti-NF--κB p105/50 RabMAb (Cat. #AJ1535a), dilution 1:5,000.Application
B. Immunohistochemical analysis of paraffin-embedded human prostate carcinoma using anti-NF--κB p105/50 RabMAb (Cat. #AJ1535a).| Product Name | NF-κB Antibody (p105/p50) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | NFKB1, Nuclear factor NF-kappa-B p50 subunit, DNA-binding factor KBF1;EBP-1 |
| Clonality | Monoclonal |
|---|---|
| Clone Number | E381 |
| Host Species | Rabbit |
| Tested Applications | WBIHC |
| WB:1:500~1000 IHC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | NFKB1 Nuclear factor NF-kappa-B p50 subunit DNA-binding factor KBF1 EBP-1 |
|---|---|
| Molecular Weight(MW) | 105356 Da |
| Function | NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105 |
| Tissue Specificity | A synthetic peptide corresponding to residues in the nuclear factor NF-κB p50 subunit was used as immunogen. This antibody will detect both forms; p50 and p105. |
| Cellular Localization | Nucleus. Cytoplasm. Note=Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B) |
| Entrez Gene | 4790 |
|---|
Application
A. Western blot analysis on Hela cell lysate using anti-NF--κB p105/50 RabMAb (Cat. #AJ1535a), dilution 1:5,000.
Application
B. Immunohistochemical analysis of paraffin-embedded human prostate carcinoma using anti-NF--κB p105/50 RabMAb (Cat. #AJ1535a).| Application Notes | WB:1:500~1000 IHC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. |
